Cochlear Ltd. shares surged on Tuesday after the Australian hearing implant manufacturer upgraded its full-year profit guidance and announced a higher dividend, citing accelerating global demand for its medical devices.
The company, which specializes in cochlear implants and bone conduction hearing solutions, said it now expects underlying profit for the 2024 financial year to rise by at least 15% from prior guidance, driven by stronger-than-anticipated sales in key markets including the United States and Europe. Cochlear also raised its interim dividend by 10% to A$1.75 per share, up from A$1.60 previously, as cash flow improved amid sustained order volumes.
Analysts at Macquarie maintained their outperform rating on Cochlear, noting that the earnings upgrade reflects robust underlying demand and pricing power in a niche but growing market for hearing solutions. The upgrade follows a period of supply chain normalization after pandemic-era disruptions, which had constrained production capacity earlier this year.
The stock, which had already gained around 15% in the prior three months, extended gains by as much as 6% in early trading, outpacing the broader S&P/ASX 200 index. Cochlear has been a standout performer in Australia’s healthcare sector, benefiting from an aging global population and increasing awareness of hearing loss treatments.
The company’s devices, which restore hearing for people with severe to profound deafness, have seen steady adoption in both developed and emerging markets. Cochlear’s technology is particularly valued in regions with limited access to traditional hearing aids, where its implantable solutions offer long-term benefits.
Cochlear is scheduled to release its full-year results on August 15, 2024. Investors will be watching for further details on market expansion and any updates on regulatory approvals for new product lines, which could influence future growth trajectories.
